French Endocrine Society Guidance on endocrine side effects of immunotherapy

Frederic Castinetti 1, * Frédérique Albarel 1 Françoise Archambeaud 2 Jérôme Bertherat 3, 4, 5 Benjamin Bouillet 6, 7 Perrine Buffier 6 Claire Briet 8 Bertrand Cariou 9 Philippe Caron 10 Olivier Chabre 11 Philippe Chanson 12 Christine Cortet 13 Christine Do Cao 13 Delphine Drui 14 Magali Haissaguerre 15 Ségolène Hescot 12 Frédéric Illouz 16 Emmanuelle Kuhn 17 Najiba Lahlou 18 Emilie Merlen 13 Véronique Raverot 19 Sarra Smati 20 Bruno Vergès 7, 6 Françoise Borson-Chazot 21
Abstract : The management of cancer patients has changed due to the considerably more frequent use of immune checkpoint inhibitors (ICPI). However, the use of ICPI has a risk of side-effects, particularly endocrine toxicity. Since the indications for ICPI are constantly expanding due to their efficacy, it is important that endocrinologists and oncologists know how to look for this type of toxicity and how to treat it when it arises. In view of this, the French Endocrine Society initiated the formulation of a consensus document on ICPI-related endocrine toxicity. In this paper, we will introduce data on the general pathophysiology of endocrine toxicity, we will then outline expert opinion focusing primarily on methods for screening, management and monitoring for endocrine side-effects in patients treated by ICPI. We will then look in turn at endocrinopathies that are induced by ICPI including dysthyroidism, hypophysitis, primary adrenal insufficiency and fulminant diabetes. In each chapter, expert opinion will be given on the diagnosis, management and monitoring for each complication. These expert opinions will also discuss the methodology for categorizing these side-effects in oncology using 'Common terminology criteria for adverse events' (CTCAE) and the difficulties in applying this to endocrine side-effects in the case of these anti-cancer therapies. This is shown in particular by certain recommendations that are used for other side-effects (high-dose corticosteroids, contra-indicated in ICPI for example), and that cannot be considered as appropriate in the management of endocrine toxicity, as it usually does not require ICPI withdrawal or high dose glucocorticoid intake .
Type de document :
Article dans une revue
Liste complète des métadonnées
Contributeur : Lnc - Université de Bourgogne <>
Soumis le : vendredi 18 janvier 2019 - 18:15:48
Dernière modification le : mardi 26 novembre 2019 - 16:11:33

Lien texte intégral



Frederic Castinetti, Frédérique Albarel, Françoise Archambeaud, Jérôme Bertherat, Benjamin Bouillet, et al.. French Endocrine Society Guidance on endocrine side effects of immunotherapy. Endocrine-Related Cancer, BioScientifica, In press, 26 (2), pp.G1-G18. ⟨10.1530/ERC-18-0320⟩. ⟨hal-01986506⟩



Consultations de la notice